Provigil vs Vyvanse: How to Switch Between Them Safely

What Are Provigil and Vyvanse, and Why Compare Them?

Provigil (modafinil) and Vyvanse (lisdexamfetamine) occupy adjacent but distinct territories in cognitive pharmacology. Modafinil is a Schedule IV wakefulness-promoting agent approved by the FDA for narcolepsy, obstructive sleep apnea (OSA), and shift-work disorder. Vyvanse is a Schedule II central nervous system stimulant approved for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 and older, and for moderate-to-severe binge-eating disorder (BED) in adults.

Clinicians and patients reach for both drugs when the goal is sustained attention, reduced fatigue, or sharper executive function. The drugs are sometimes compared informally in ADHD care when first-line stimulants produce intolerable side effects, and in sleep medicine when wakefulness-promoting agents need to be rotated.

Why People Switch

The most common clinical reasons for switching between these two agents include:

• Inadequate symptom control on the current agent
• Intolerable cardiovascular effects (tachycardia, hypertension) more common with Vyvanse
• Insomnia caused by either agent at higher doses
• Regulatory barriers to Schedule II refills prompting interest in Schedule IV modafinil
• Insurance formulary changes or prior-authorization denials

What This Article Covers

This comparison walks through mechanism of action, head-to-head efficacy data where it exists, safety profiles, and a structured protocol for transitioning from one drug to the other. No direct randomized controlled trial has compared modafinil against lisdexamfetamine in the same patient population; the evidence synthesis here draws from separate trial programs.

Mechanisms of Action: How Each Drug Works in the Brain

Modafinil (Provigil)

Modafinil's exact mechanism remains partially understood. The drug inhibits dopamine reuptake by binding to the dopamine transporter (DAT), but with far lower affinity than classical amphetamines. This produces smaller synaptic dopamine surges and a correspondingly lower abuse potential. Modafinil also activates orexin/hypocretin neurons in the hypothalamus, stabilizes histaminergic wake-promoting pathways, and may modestly raise norepinephrine in prefrontal regions. The net effect is sustained wakefulness without the sharp catecholamine spike that underlies amphetamine euphoria.

Lisdexamfetamine (Vyvanse)

Vyvanse is an amphetamine prodrug. After oral ingestion, intestinal and red blood cell enzymes cleave the lysine residue to release d-amphetamine. That d-amphetamine then enters nerve terminals, reverses the vesicular monoamine transporter (VMAT2), and floods synapses with dopamine, norepinephrine, and to a lesser degree serotonin. The prodrug design blunts peak plasma concentration relative to immediate-release amphetamine salts, extending duration and reducing the abuse signal from rapid-onset euphoria. The FDA-approved labeling describes lisdexamfetamine as a prodrug "converted to the active moiety d-amphetamine" after absorption.

Why the Mechanism Difference Matters Clinically

The mechanism gap explains most of the clinical differences. Vyvanse produces stronger, faster dopaminergic signaling, which generally delivers greater ADHD symptom control but also higher cardiovascular load and abuse risk. Modafinil's more diffuse wake-promoting profile suits conditions where the primary deficit is sleepiness rather than dopamine-mediated attention regulation.

Efficacy Data: What the Trials Actually Show

Modafinil in Narcolepsy and Wakefulness

The US Modafinil in Narcolepsy Study Group published foundational efficacy data in the Annals of Neurology in 1998. That double-blind, placebo-controlled trial demonstrated that modafinil at 200 mg and 400 mg daily significantly reduced Epworth Sleepiness Scale (ESS) scores compared with placebo, without the cardiovascular and dependence liability seen with amphetamine-class agents. The trial showed clinically meaningful reductions in daytime sleepiness across both dose arms with an acceptable tolerability profile.

Subsequent trials expanded modafinil's evidence base to OSA-related residual sleepiness and shift-work disorder, reinforcing the drug's utility as a wakefulness agent in populations where circadian disruption drives cognitive impairment.

Lisdexamfetamine in ADHD

Wigal and colleagues published long-term ADHD symptom data in the Journal of Attention Disorders in 2017. That open-label extension study documented sustained ADHD symptom reduction over 12 to 13 hours of coverage, with ADHD Rating Scale IV (ADHD-RS-IV) scores falling from a mean of approximately 43 at baseline to approximately 18 after 12 months of lisdexamfetamine treatment. The study enrolled children aged 6 to 12 years and reported that 73.8% of completers maintained response at endpoint.

For adult ADHD, the key Phase III trial (SPD489-325) showed that lisdexamfetamine at 30, 50, and 70 mg daily produced statistically significant improvements versus placebo on the Conners' Adult ADHD Rating Scale (CAARS), with the 70-mg arm showing the largest effect (P<0.001). This trial underpinned the initial FDA approval for adult ADHD.

Off-Label Modafinil for ADHD

Off-label use of modafinil in ADHD has some trial support. A 2006 meta-analysis in Biological Psychiatry reviewed six double-blind, placebo-controlled trials (total N=933) and found that modafinil produced statistically significant improvements in ADHD symptoms versus placebo, though effect sizes were smaller than those reported for amphetamine-class agents. That analysis is available at PubMed. No FDA indication for ADHD was granted, partly because of one pediatric case report of Stevens-Johnson syndrome.

No Direct Head-to-Head Trial

No published randomized controlled trial has directly compared modafinil against lisdexamfetamine in the same patient population, for the same indication, at the same time. Any claim of superiority between these two agents is therefore based on cross-trial inference, which carries inherent limitations in population matching, outcome measures, and study design.

Side-Effect Profiles: Where the Drugs Diverge Most

Shared Side Effects

Both agents commonly cause:

• Insomnia (modafinil: 5 to 10% in trials; lisdexamfetamine: 11 to 19% across age groups)
• Headache (modafinil: 34% in the narcolepsy trial; lisdexamfetamine: 14 to 26%)
• Decreased appetite (more pronounced with Vyvanse)
• Nausea

Cardiovascular Burden

This is where the profiles split sharply. Vyvanse carries a black-box warning for serious cardiovascular events in patients with pre-existing structural cardiac abnormalities. Across clinical trial programs, lisdexamfetamine increased mean heart rate by 3 to 5 bpm and systolic blood pressure by 1 to 4 mmHg. The FDA prescribing information recommends that patients with known serious cardiac conditions generally should not receive Vyvanse.

Modafinil also raises blood pressure modestly, but the magnitude is smaller and the mechanism less catecholaminergic. A post-marketing cardiovascular analysis showed mean increases of 1 to 2 mmHg systolic and <1 bpm heart rate, substantially below Vyvanse's profile.

Psychiatric Effects

Both drugs can precipitate or worsen psychosis, mania, and anxiety in susceptible individuals. Vyvanse's stronger dopaminergic signal makes psychiatric adverse events more likely in patients with a personal or family history of bipolar disorder or psychotic illness. The American Heart Association published guidance recommending cardiac evaluation before initiating stimulants.

Abuse and Dependence

Vyvanse is Schedule II because amphetamines carry substantial abuse and dependence potential. The prodrug design reduces but does not eliminate that risk. Modafinil is Schedule IV, reflecting a lower but non-zero abuse profile. Patients with a substance use disorder history may present lower risk on modafinil, though neither drug is risk-free in that population.

Weight and Growth

Appetite suppression is stronger with lisdexamfetamine. In pediatric patients, sustained appetite suppression may slow growth velocity. The Wigal 2017 long-term study tracked height and weight z-scores; small but statistically significant decrements were observed over 12 months. Growth monitoring is recommended throughout pediatric stimulant treatment.

Regulatory and Prescribing Differences

Modafinil sits at DEA Schedule IV, meaning up to five refills are permitted on a single prescription in most US states and electronic prescribing is standard. Vyvanse is Schedule II: no refills permitted, a new prescription is required each month, and many states mandate electronic prescriptions through PDMP-monitored systems.

These regulatory realities influence switching decisions more than prescribers often acknowledge. A patient transitioning from Vyvanse to modafinil gains prescription flexibility and reduced pharmacy barriers. The reverse transition carries more administrative burden.

Insurance coverage also differs. Many commercial plans tier Vyvanse as a brand-only Schedule II with prior-authorization requirements. Generic modafinil has been available since 2012 and costs substantially less, often $20 to $40 per month at standard doses without insurance.

How to Switch From Provigil to Vyvanse

The following protocol reflects standard clinical practice synthesized from the FDA labeling of both agents, cardiovascular guidance from the American Heart Association, and published pharmacokinetic data. It has not been validated in a prospective trial.

Step 1: Pre-Switch Assessment

Before initiating Vyvanse, the prescriber should:

1. Record baseline heart rate and blood pressure (two readings, seated, two minutes apart).
2. Screen for personal or family history of structural heart disease, arrhythmia, or sudden cardiac death.
3. Assess for personal or family history of bipolar disorder, psychosis, or substance use disorder.
4. Confirm the patient is not pregnant (Category C; teratogenic risk exists in animal studies).
5. Review current medications for CYP3A4 interactions, as modafinil induces CYP3A4 and may reduce plasma levels of hormonal contraceptives and other CYP3A4-sensitive drugs.

Step 2: Last Dose of Modafinil and Washout

Modafinil's half-life is approximately 15 hours (range 10 to 20 hours across individuals). A 24-hour interval between the last modafinil dose and the first Vyvanse dose allows for approximately 1.5 half-lives of clearance, reducing the risk of additive cardiovascular stimulation during the transition period.

No taper is required when discontinuing modafinil. Abrupt cessation is generally well tolerated, though some patients report 1 to 2 days of rebound fatigue.

Step 3: Starting Vyvanse

Begin at the lowest approved dose: 20 mg in the morning for adults or 20 to 30 mg for pediatric patients. Do not start at a dose equivalent to the modafinil dose being replaced; the pharmacodynamic potency per milligram is not comparable. Titrate in 10-mg increments at weekly intervals based on response and tolerability. The maximum approved dose is 70 mg per day.

Step 4: Monitoring After the Switch

• Recheck heart rate and blood pressure at one week and again at four weeks.
• Ask specifically about insomnia. The two drugs have overlapping wake-promoting activity; some patients find Vyvanse's sharper onset more new to sleep even when the dose is lower.
• Monitor weight and appetite weekly for the first month.
• Reassess ADHD or sleepiness symptoms at four weeks using a validated scale (ADHD-RS-IV for ADHD; ESS for hypersomnolence).

How to Switch From Vyvanse to Provigil

Transitioning from Vyvanse to modafinil is typically undertaken when a patient experiences intolerable cardiovascular side effects, psychiatric adverse events, or has a regulatory or preference-based reason to move to a Schedule IV agent.

Step 1: Pre-Switch Assessment

Confirm the prescriber's reason for switching and document it. If the switch is driven by cardiovascular concerns, obtain a repeat blood pressure and pulse. If psychiatric adverse events prompted the change, ensure no active psychotic or manic symptoms are present before starting modafinil (which also carries a psychiatric adverse event warning, albeit a smaller one).

Step 2: Vyvanse Washout

D-amphetamine's half-life after Vyvanse hydrolysis is approximately 10 to 13 hours. A 24-hour washout after the last Vyvanse dose is adequate for most patients. In patients who experienced significant cardiovascular effects, a 48-hour washout is prudent.

No Vyvanse taper is required for most patients, but some individuals on higher doses (50 to 70 mg) may experience 2 to 4 days of fatigue, low mood, and increased appetite after stopping. This post-amphetamine dysphoria is self-limiting and does not require pharmacological management in the majority of cases. Preparing the patient for this window improves adherence.

Step 3: Starting Modafinil

Begin at 100 mg in the morning. The approved dose range is 100 to 400 mg daily. For narcolepsy and OSA, 200 mg daily is the standard starting dose per FDA labeling. For shift-work disorder, 200 mg taken one hour before the shift begins is the labeled approach. Titrate based on wakefulness response and tolerability, not on the prior Vyvanse dose.

Step 4: Managing Expectations

This is a common point of dissatisfaction. Patients who were on Vyvanse for ADHD may find that modafinil's wakefulness-promoting effect does not replicate Vyvanse's focused-attention and impulse-control benefits. Modafinil is not FDA-approved for ADHD, and the off-label evidence suggests a smaller effect size. Set explicit expectations before the switch: the trade-off is a safer cardiovascular and regulatory profile against potentially less strong ADHD symptom control.

A 2003 practice statement from the American Academy of Sleep Medicine notes that wakefulness-promoting agents like modafinil are not equivalent to dopaminergic stimulants in disorders primarily defined by attentional dysregulation. That guidance is accessible through the AASM's archived publications.

Who Should Use Modafinil vs Vyvanse: A Clinical Decision Framework

The table below captures the decision points most commonly encountered in clinical practice.

| Clinical Scenario | Preferred Agent | Reason | |---|---|---| | Narcolepsy or OSA residual sleepiness | Modafinil | FDA-approved; lower cardiovascular risk | | ADHD with normal cardiovascular profile | Vyvanse | FDA-approved; stronger evidence base | | ADHD with hypertension or tachycardia | Modafinil (off-label) | Lower cardiovascular burden | | Shift-work disorder | Modafinil | FDA-approved indication | | Substance use disorder history | Modafinil (with caution) | Schedule IV; lower abuse potential | | Binge-eating disorder | Vyvanse | Only FDA-approved pharmacotherapy for BED | | Formulary cost-sensitive patient | Modafinil generic | Generic available since 2012; significantly lower cost | | Prior psychiatric adverse event on stimulants | Neither without specialist input | Both carry psychiatric warnings |

Drug Interactions to Know Before Switching

Both modafinil and lisdexamfetamine have clinically significant drug interactions that must be reviewed at the time of any switch.

Modafinil as a CYP Inducer

Modafinil induces CYP3A4 and CYP2C9 and inhibits CYP2C19. This produces several clinically significant interactions:

• Hormonal contraceptives: CYP3A4 induction can reduce ethinyl estradiol exposure by up to 20%. Patients switching to modafinil should use a non-hormonal backup contraceptive method during modafinil use and for one month after stopping.
• Cyclosporine: Plasma levels may drop significantly; therapeutic drug monitoring is required.
• Warfarin: CYP2C9 inhibition by modafinil may increase warfarin exposure; check INR more frequently at initiation.

Vyvanse and Monoamine Oxidase Inhibitors

Combining lisdexamfetamine with a monoamine oxidase inhibitor (MAOI) is contraindicated and potentially fatal. MAOIs inhibit amphetamine metabolism, causing severe hyperthermia, hypertension, and seizure. The FDA labeling specifies a minimum 14-day washout after any MAOI before starting Vyvanse. This washout requirement applies in reverse as well.

Serotonergic Agents

Both drugs modestly raise serotonin in some pathways. Co-prescribing with serotonergic medications (SSRIs, SNRIs, triptans, tramadol) warrants awareness, though frank serotonin syndrome is uncommon at standard doses.

Special Populations

Pregnancy

Both modafinil and lisdexamfetamine are Pregnancy Category C. Animal studies show modafinil produces embryolethality and fetal structural abnormalities at doses equivalent to human therapeutic exposure. The FDA prescribing information for modafinil cautions against use in pregnancy absent compelling clinical need. Lisdexamfetamine carries similar teratogenic signal in animal data, plus risk of premature delivery and neonatal withdrawal in case reports. Switching drugs during pregnancy does not reduce risk; ideally, both are discontinued under medical supervision before conception.

Hepatic Impairment

Modafinil is hepatically metabolized; dose should be halved in severe hepatic impairment per labeling. Lisdexamfetamine's enzymatic hydrolysis occurs in the blood and gut, making hepatic impairment less impactful on pharmacokinetics, though careful titration is still warranted.

Renal Impairment

Lisdexamfetamine's prodrug step is not renally cleared, but d-amphetamine's renal excretion does increase at lower urinary pH. Modafinil's major metabolite modafinil acid is renally excreted; dose adjustment is generally not required for mild-to-moderate renal impairment but should be considered if GFR falls below 30 mL/min/1.73m².

Older Adults

Neither drug has strong safety data in patients over 65. Modafinil's wake-promoting properties may benefit older patients with excessive daytime sleepiness, but age-related CYP reductions prolong half-life and may necessitate lower doses (100 mg). Amphetamine-class agents carry greater fall-risk and cardiovascular concern in older populations and should generally be avoided without specialist oversight.